Indications
Treatment of seizures associated with Dravet syndrome as an add-on therapy to other antiepileptic medicines for patients 2 years of age and older. Fintepla is indicated for the treatment of seizures associated with Dravet syndrome and Lennox-Gastaut syndrome as an add-on therapy to other anti-epileptic medicines for patients 2 years of age and older.
Composition
- Active substance
- fenfluramine hydrochloride
- International name (INN)
- fenfluramine
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Fintepla
- Active substance
- fenfluramine hydrochloride
- ATC code
- N03
- Group
- Nervous system
- Therapeutic area
- Epilepsies, Myoclonic